Replies to post #172446 on Biotech Values

[oc631]

It is quite possible that ENTA acquisition discussions are taking place already and these discussions are not going well.

Discussions are not going well between ABBV and ENTA or not going well amongst the ENTA BOD? Ousting directors could be one way to settle an argument. Investors banking on a sale of the company may look at this as a negative event and an attempt by Luly to keep the company independent. I personally see value in the company regardless of outcome.


You made statements you claim are factual. Do you have an inside source on what's going on at ENTA?

[oc631]

It is quite possible that ENTA acquisition discussions are taking place already and these discussions are not going well.

Just a fact that may (or may not) have a bearing on the timing of a potential deal with ABBV. The composition and use patents for ABT-450 have not yet issued. ABBV may be waiting for these patents to clear before deciding when (or if) they will make an offer for ENTA. Note: ABBV and ENTA worked together on the protease class assets (including ABT-450).

[DewDiligence]

ENTA—The facts: • Goldberg and Poorvin resignation indicates that a major conflict is taking place on the ENTA BoD.

I don’t think it’s a foregone conclusion that there is a major conflict on the existing BoD. If there were, the statement in ENTA’s 8-K that the resignations are “not the result of any disagreement with Enanta on any matter relating to its operations, policies or practices” would be untrue and might be legally actionable.

An alternative explanation (the one mentioned in #msg-95809197) is that the impetus for the resignations is to shrink the board size to give more power to each director, especially Luly.

It is expected that, following a completion of HCV registration trials with ABBV, ENTA will be sold (unless the expected results are a complete failure).

Expected by whom?